Biesterfeld

Photo

Statement: Customer Centricity is Key

The chemical distribution outlook report by Boston Consulting Group, outlined on the previous pages, presents six key findings that capture the strategic pressures and capability shifts transforming the chemical disgtribution landscape, setting the stage for four imperatives that will help distributors to win amid uncertainty. Madjar Navah, one of the authors of the report, introduced the most significant results of the study at the FECC Annual Meeting in Hamburg, Germany, in mid-September. Among the audience were executives of the largest chemical distribution companies, some of which we asked to share their opinions on the report’s conclusions with us.

Photo

Transforming Distribution Strategies

Experts of Ataman Chemicals, Barentz, Biesterfeld, Brenntag, BÜFA Chemicals, CSC Jaeklechemie, Häffner, IMCD, Krahn Chemie, Möller Chemie, Nordmann, RN Chemicals, and Stockmeier share their opinions

Photo

Statement: Stephan Glander, CEO, Biesterfeld

CHEManager asked executives and industry experts from a broad range of chemical distributors to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.

Photo

Biesterfeld Takes Majority of GME Chemicals

Hamburg-based German distributor Biesterfeld has closed its acquisition of a majority stake in Singapore-based GME Chemicals. The distributor did not quantify the size of the stake but said it plans to purchase the remaining shares over a five-year period. The parties have agreed not to disclose details of the transaction, which will leave GME’s management team and employees in place.

Photo

Circular Economy

The chemical industry is on the threshold of a new era – the age of circularity. We asked industry experts to share their opinions on this transformational topic.

Photo

Service Is at the Core of Our Business Model

“Harke Group started very early, around end of the 90s, with the process of digital transformation, so that we can meanwhile look back to almost two decades of experience in this area. We therefore see for us rather chances than risks in it.

43 more articles

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.